CD8A and neoplasm: In colon cancer, the introduction of the Immunoscore, an immunohistochemistry (IHC) and digital pathology-based assay which quantifies CD3 + and CD8 + T cells in the tumour core and invasive margin, has been shown to predict patients who will benefit from adjuvant chemotherapy [11].